Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs BI 655130 (Primary)
- Indications Palmoplantar pustulosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 14 Nov 2017 Planned End Date changed from 29 Jun 2018 to 31 Aug 2018.
- 14 Nov 2017 Planned primary completion date changed from 9 Mar 2018 to 11 May 2018.
- 05 Jun 2017 Status changed from not yet recruiting to recruiting.